Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0370220200640040327
Yakhak Hoeji
2020 Volume.64 No. 4 p.327 ~ p.333
Efficacy of ID-GMG001 for the Alleviation of Hangover: A Randomized, Double-blind, Placebo-controlled, Crossover Human Study
Kim Min-Cheol

Park Ha-Young
Park Jong-Mi
Lim Hyun-Jung
Park Ju-Hyun
Chun Gul-Soon
Lee Dong-Han
Abstract
This randomized, double-blind, placebo-controlled, crossover human study aimed to investigate the efficacy ofID-GMG001 for the alleviation of hangover in men between the ages of 20 and 50 years. The selected subjects wererandomized to an ID-GMG001 group and a placebo group. Two overnight assessments were conducted at KyungheeUniversity Hospital exactly one week apart and at the same time of day. The subjects ingested placebo or ID-GMG001and then consumed alcohol 30 minutes later to induce hangover. The efficacy of ID-GMG001 for alleviating hangover wasdetermined based on serum acetaldehyde levels over time. After the experiment, the results of 21 subjects who met theassessment criteria (per-protocol set) were analyzed. Comparisons of area under the curve (AUC; p=0.032), dose at 4 and6 hours after alcohol consumption (p=0.001 and p=0.008, respectively), showed that serum acetaldehyde concentrationswere significantly lower in the ID-GMG001 group than in the placebo group. A safety assessment revealed no serious IDGMG001-related adverse events, and no significant changes in vital signs and laboratory parameters occurred that couldhave affected patient safety. In conclusion, we determined that the use of ID-GMG001 before alcohol consumptioneffectively alleviates hangover in adults by reducing serum acetaldehyde concentrations.
KEYWORD
ID-GMG001, hangover, alcohol, acetaldehyde, serum acetaldehyde concentrations
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI)